EAU 2012 Report – Ideas to get men talking to GPs about BPH
25 Feb 2012 – EAU Paris – Men often finds it difficult to talk with primary health specialists and this is certainly true in the case of BPH.
25 Feb 2012 – EAU Paris – Men often finds it difficult to talk with primary health specialists and this is certainly true in the case of BPH.
It is estimated that as many as 24 million European men aged 50 and over experience bothersome urinary symptoms.1,2 Yet, despite experiencing symptoms, men typically wait nearly two… read more.
26 Feb 2012 – EAU Paris, France – What have been some of the EAU highlights to date? And what are some Key messages to share with Irish… read more.
Conclusions of the ICD for Life Summit held in Belgrade, Serbia “Implantable devices can save lives and decrease mortality, they are not a luxury”
by Edel O’Connell reporting on the presentation by Professor Eoin O’Brien.
by Edel O’Connell reporting on the presentation by Dr. Stephen Horgan.
The European Society for Medical Oncology (ESMO) has awarded ESMO Designated Center of Integrated Oncology and Palliative Care accreditation to 16 new oncology centres.
The Brussels Declaration, published in the European Respiratory Journal in 2008 recognises the high prevalence of patients with poorly controlled asthma and calls for changes in asthma management… read more.
The combination also appears to be cost effective. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with… read more.
by Bruce Sylvester – Revamped ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (STEMI) include issues of diagnosis and treatment before,… read more.
by Bruce Sylvester – Revamped ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (STEMI) include issues of diagnosis and treatment before,… read more.
In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.